Omalizumab (Xolair) is a monoclonal antibody that can significantly relieve symptoms in patients with Allergic Bronchopulmonary Aspergillosis (ABPA) by targeting the underlying allergic response.
Here’s how it works and why it helps:
🧬 Mechanism of Action
-
Omalizumab binds to free IgE antibodies in the blood.
-
This prevents IgE from attaching to immune cells (like mast cells and basophils), blocking the allergic cascade.
-
Over time, this leads to downregulation of IgE receptors, reducing immune hypersensitivity.
🩺 Benefits for Patients with ABPA
ABPA is driven by an IgE-mediated hypersensitivity to Aspergillus fumigatus, so omalizumab directly targets a key driver of the disease.
✅ Key Clinical Effects:
| Effect | How Omalizumab Helps |
|---|---|
| Reduces airway inflammation | By calming the immune overreaction to Aspergillus |
| Improves asthma control | Fewer exacerbations and better lung function |
| Lowers total IgE levels | A marker of disease activity in ABPA |
| Reduces corticosteroid use | Helps wean off oral steroids safely |
| Improves quality of life | Less coughing, breathlessness, mucus plugging |
📊 Who Responds Best?
-
Patients with uncontrolled ABPA despite steroids and antifungals
-
Those with frequent exacerbations or steroid dependency
-
Particularly helpful in patients with asthma + ABPA
⚠️ Notes
-
Omalizumab is given by injection every 2–4 weeks (dose based on weight and IgE levels).
-
It is not a cure for ABPA but can significantly reduce flare-ups and steroid need.
-
Not all patients respond — monitoring is essential.
Latest News posts
News archive